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ABSTRACT 
  
Hepatitis E virus (HEV), the major aetiologic agent of enterically 
transmitted non A, non B hepatitis worldwide. During the period between 
October 2004 and April 2005 a cross sectional hospital – based study, 
was conducted in Khartoum Teaching Hospital to investigate the 
prevalence of acute hepatitis E among Sudanese patients presenting with 
acute hepatitis.  
All patients presented with acute hepatitis were screened for viral 
hepatitis (A, B, C, E). Eleven out of fifty patients studied patients were 
found to have hepatitis E IgM antibodies (22%). 
In our study no difference was found in the clinical presentation 
between hepatitis E infection and other viral hepatitis, nevertheless,                 
a high incidence of fulminant hepatic failure was observed in patients 
with hepatitis E infection (2 out of 11 patients). 
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  اﻟﺨﻼﺻــــــﺔ
م إﻟﻰ اﺑﺮﻳﻞ 4002     هﺬﻩ دراﺳﺔ ﻣﻘﻄﻌﻴﺔ أﺟﺮﻳﺖ ﻓﻲ ﻣﺴﺘﺸﻔﻰ اﻟﺨﺮﻃﻮم ﻓﻲ اﻟﻔﺘﺮة ﻣﺎ ﺑﻴﻦ أآﺘﻮﺑﺮ 
  .م5002
ﺑﺎﻟﻨﺴﺒﺔ ﻟﻼﻟﺘﻬﺎب ﺑﺄﻧﻮاع ( E)   هﺪﻓﺖ اﻟﺪراﺳﺔ ﻟﻤﻌﺮﻓﺔ ﻧﺴﺒﺔ اﻧﺘﺸﺎر اﻟﺘﻬﺎب اﻟﻜﺒﺪ ﺑﺎﻟﻔﻴﺮوس هـ 
  .ﻓﻴﺮوﺳﺎت اﻟﻜﺒﺪ اﻟﻮﺑﺎﺋﻲ اﻷﺧﺮى ﻓﻲ اﻟﺴﻮدان
 ﺣﺎﻟﺔ ﻣﺼﺎﺑﺔ ﺑﺎﻟﺘﻬﺎب اﻟﻜﺒﺪ 11 ﺣﺎﻟﺔ ﻣﺼﺎﺑﺔ ﺑﺎﻟﺘﻬﺎب اﻟﻜﺒﺪ اﻟﺤﺎد ووﺟﺪ ﻣﻦ ﺑﻴﻨﻬﺎ 05   أﺧﺬت 
  %.22( E)ﺑﺎﻟﻔﻴﺮوس هـ 
  اﺛﺒﺘﺖ اﻟﺪراﺳﺔ اﻧﻪ ﻟﻴﺲ هﻨﺎك ﻓﺮق واﺿﺢ ﻓﻲ اﻷﻋﺮاض اﻟﺴﺮﻳﺮﻳﺔ ﺑﻴﻦ اﻟﺘﻬﺎب اﻟﻜﺒﺪ ﺑﺎﻟﻔﻴﺮوس 
أدى إﻟﻰ واﻟﻔﻴﺮوﺳﺎت اﻷﺧﺮى ، وﻟﻜﻦ وﺟﺪ ﻟﺪﻳﻬﻢ ﻧﺴﺒﺔ ﻋﺎﻟﻴﺔ ﻣﻦ ﻓﺸﻞ اﻟﻜﺒﺪ اﻟﺤﺎد اﻟﺬي ( E)هـ 
  .E( ﻣﺼﺎب ﺑﺎﻟﺘﻬﺎب اﻟﻜﺒﺪ ﺑﺎﻟﻔﻴﺮوس 11ﻣﺼﺎﺑﻴﻦ ﻣﻦ ﺑﻴﻦ )اﻟﻮﻓﺎة 
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INTRODUCTION 
 
Acute viral hepatitis is a systemic infection affecting the liver 
predominantly. Almost all cases of acute viral hepatitis are caused by one of 
five viral agents: hepatitis A virus (HAV), hepatitis B virus (HBV), hepatitis 
C virus (HCV), the HBV-associated delta agent or hepatitis D virus (HDV), 
and hepatitis E virus (HEV). Other transfusion-transmitted agents, e.g., 
"hepatitis G" virus and  "TT" virus, have been identified but do not cause 
hepatitis. All these human hepatitis viruses are RNA viruses, except for 
hepatitis B, which is a DNA virus. Although these agents can be 
distinguished by their molecular and antigenic properties, all types of viral 
hepatitis produce clinically similar illnesses. These range from 
asymptomatic and in apparent to fulminant and fatal acute infections 
common to all types, on the one hand, and from subclinical persistent 
infections to rapidly progressive chronic liver disease with cirrhosis and 
even hepatocellular carcinoma, common to the bloodborne types (HBV, 
HCV, and HDV), on the other hand(1).   
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LITERATURE REVIEW 
 
ACUTE VIRAL HEPATITIS 
VIROLOGY AND ETIOLOGY:- 
Hepatitis A 
 Hepatitis A virus is a non-enveloped 27-nm, heat-, acid-, and ether-resistant 
RNA virus in the hepatovirus genus of the picornavirus family. Hepatitis A 
has an incubation period of approximately 4 weeks. Its replication is limited 
to the liver, but the virus is present in the liver, bile, stools, and blood during 
the late incubation period and acute preicteric phase of illness. Despite 
persistence of virus in the liver, viral shedding in feces, viremia, and 
infectivity diminish rapidly once jaundice becomes apparent. HAV is the 
only one of the human hepatitis viruses that can be cultivated reproducibly 
in vitro(2,3).   
Antibodies to HAV (anti-HAV) can be detected during acute illness when 
serum aminotransferase activity is elevated and fecal HAV shedding is still 
occurring. This early antibody response is predominantly of the IgM class 
and persists for several months, rarely for 6 to 12 months. During 
convalescence, however, anti-HAV of the IgG class becomes the 
predominant antibody . Therefore, the diagnosis of hepatitis A is made 
during acute illness by demonstrating anti-HAV of the IgM class. After 
acute illness, anti-HAV of the IgG class remains detectable indefinitely, and 
patients with serum anti-HAV are immune to reinfection. Neutralizing 
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antibody activity parallels the appearance of anti-HAV, and the IgG anti-
HAV present in immune globulin accounts for the protection it affords 
against HAV infection(2,3).   
Hepatitis B  
 Hepatitis B virus is a DNA virus with a remarkably compact genomic 
structure; despite its small, circular, 3200-basepair size(4).    
Viral proteins and particles  . The envelope protein expressed on the outer 
surface of the virion and on the smaller spherical and tubular structures is 
referred to as hepatitis B surface antigen (HBsAg),.. The antigen expressed 
on the surface of the nucleocapsid core is referred to as hepatitis B core 
antigen (HBcAg), and its corresponding antibody is anti-HBc. A third HBV 
antigen is hepatitis B e antigen (HBeAg), a soluble, nonparticulate, 
nucleocapsid (4).   
Serologic and virologic markers  After infection with HBV, the first 
virologic marker detectable in serum is HBsAg). Circulating HBsAg 
precedes elevations of serum aminotransferase activity and clinical 
symptoms and remains detectable during the entire icteric or symptomatic 
phase of acute hepatitis B and beyond. In typical cases, HBsAg becomes 
undetectable 1 to 2 months after the onset of jaundice and rarely persists 
beyond 6 months. After HBsAg disappears, antibody to HBsAg (anti-HBs) 
becomes detectable in serum and remains detectable indefinitely thereafter. 
Because HBcAg is sequestered within an HBsAg coat, HBcAg is not 
detectable routinely in the serum of patients with HBV infection. By 
contrast, anti-HBc is readily demonstrable in serum, beginning within the 
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first 1 to 2 weeks after the appearance of HBsAg and preceding detectable 
levels of anti-HBs by weeks to months. Because variability exists in the time 
of appearance of anti-HBs after HBV infection, occasionally a gap of 
several weeks or longer may separate the disappearance of HBsAg and the 
appearance of anti-HBs. During this "gap" or "window" period, anti-HBc 
may represent serologic evidence of current or recent HBV infection, and 
blood containing anti-HBc in the absence of HBsAg and anti-HBs has been 
implicated in the development of transfusion-associated hepatitis B. In part 
because the sensitivity of immunoassays for HBsAg and anti-HBs has 
increased, however, this window period is rarely encountered(4-10).  
Early during the course of acute hepatitis B, HBeAg appears transiently; its 
disappearance may be a harbinger of clinical improvement and resolution of 
infection. Persistence of HBeAg in serum beyond the first 3 months of acute 
infection may be predictive of the development of chronic infection(5).  
Hepatitis D  The delta hepatitis agent, or HDV, is a defective RNA virus 
that coinfects with and requires the helper function of HBV (or other 
hepadnaviruses) for its replication and expression. Slightly smaller than 
HBV, delta is a formalin-sensitive, 35- to 37-nm virus with a hybrid 
structure. The delta core is "encapsidated" by an outer envelope of HBsAg, 
indistinguishable from that of HBV except in its relative compositions of 
major, middle, and large HBsAg component proteins. Although complete 
hepatitis D virions and liver injury require the cooperative helper function of 
HBV, intracellular replication of HDV RNA can occur without HBV(11,12).            
During acute HDV infection, anti-HDV of the IgM class predominates, and 
30 to 40 days may elapse after symptoms appear before anti-HDV can be 
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detected. In self-limited infection, anti-HDV is low titer and transient, rarely 
remaining detectable beyond the clearance of HBsAg and HDV antigen(11,12).    
Hepatitis C  
 Hepatitis C virus, which, before its identification was labeled "non-A, non-
B hepatitis," is a linear, single-stranded, positive-sense, 9400-nucleotide 
RNA virus,. The HCV genome contains a single large open reading frame 
(gene) that codes for a virus polyprotein of approximately 3000 amino 
acids(13).   
The most sensitive indicator is the presence of HCV RNA, which requires 
molecular amplification by polymerase chain reaction (PCR)). In most 
patients with acute hepatitis C, antibody detected appears between 1 to 3 
months after the onset of acute hepatitis but sometimes not for a year or 
longer(14,16).   
PATHOLOGY: 
The typical morphologic lesions of all types of viral hepatitis are similar and 
consist of panlobular infiltration with mononuclear cells, hepatic cell 
necrosis, hyperplasia of Kupffer cells, and variable degrees of cholestasis. 
The mononuclear infiltration consists primarily of small lymphocytes, 
although plasma cells and eosinophils occasionally are present. Liver cell 
damage consists of hepatic cell degeneration and necrosis, cell dropout, 
ballooning of cells, and acidophilic degeneration of hepatocytes (forming 
so-called Councilman bodies. In uncomplicated viral hepatitis, the reticulin 
framework is preserved(17).   
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In hepatitis C, the histologic lesion is often remarkable for a relative paucity 
of inflammation, a marked increase in activation of sinusoidal lining cells, 
lymphoid aggregates, the presence of fat, and, occasionally, bile duct lesions 
in which biliary epithelial cells appear to be piled up without interruption of 
the basement membrane. Occasionally, microvesicular steatosis occurs in 
hepatitis D. A cholestatic variant of slowly resolving acute hepatitis A also 
has been described(13-16).   
In massive hepatic necrosis (fulminant hepatitis, acute yellow atrophy), the 
striking feature at postmortem examination is the finding of a small, 
shrunken, soft liver. Histologic examination reveals massive necrosis and 
dropout of liver cells of most lobules with extensive collapse and 
condensation of the reticulin framework (18,19).   
EPIDEMIOLOGY: 
Hepatitis A  
 This agent is transmitted almost exclusively by the fecal-oral route. Person-
to-person spread of HAV is enhanced by poor personal hygiene and 
overcrowding; large outbreaks as well as sporadic cases have been traced to 
contaminated food, water, milk, frozen raspberries and strawberries, and 
shellfish. Intrafamily and intrainstitutional spread are also common. Early 
epidemiologic observations suggested that there is a predilection for 
hepatitis A to occur in late fall and early winter. In temperate zones, 
epidemic waves have been recorded every 5 to 20 years as new segments of 
nonimmune population appeared; however, in developed countries, the 
incidence of type A hepatitis has been declining, presumably as a function 
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of improved sanitation, and these cyclic patterns are no longer being 
observed. No HAV carrier state has been identified after acute type A 
hepatitis(2,3).   
Hepatitis B 
  Percutaneous inoculation has long been recognized as a major route of 
hepatitis B transmission, but the outmoded designation "serum hepatitis" is 
an inaccurate label for the epidemiologic spectrum of HBV infection 
recognized today. As detailed below, most of the hepatitis transmitted by 
blood transfusion is not caused by HBV; moreover, in approximately two-
thirds of patients with acute type B hepatitis, there is no history of an 
identifiable percutaneous exposure.. HBsAg has been identified in almost 
every body fluid from infected persons, and at least some of these body 
fluidsmost notably semen and salivaare infectious, albeit less so than serum, 
when administered percutaneously or nonpercutaneously to experimental 
animals. Among the nonpercutaneous modes of HBV transmission, oral 
ingestion has been documented as a potential but inefficient route of 
exposure. By contrast, the two nonpercutaneous routes considered to have 
the greatest impact are intimate (especially sexual) contact and perinatal 
transmission(4-6).    
Perinatal transmission occurs primarily in infants born to HBsAg carrier 
mothers or mothers with acute hepatitis B during the third trimester of 
pregnancy or during the early postpartum period. Perinatal transmission is 
uncommon in North America and western Europe but occurs with great 
frequency and is the most important mode of HBV perpetuation in the Far 
East and developing countries. Although the precise mode of perinatal 
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transmission is unknown, and although approximately 10% of infections 
may be acquired in utero, epidemiologic evidence suggests that most 
infections occur approximately at the time of delivery and are not related to 
breast feeding. The likelihood of perinatal transmission of HBV correlates 
with the presence of HBeAg; 90% of HBeAg-positive mothers but only 10 
to 15% of anti-HBe-positive mothers transmit HBV infection to their 
offspring(5).  
The more than 350 million HBsAg carriers in the world constitute the main 
reservoir of hepatitis B in human beings. Serum HBsAg is infrequent (0.1 to 
0.5%) in normal populations in the United States and western Europe. 
However, a prevalence of up to 5 to 20% has been found in the Far East and 
in some tropical countries; in persons with Down's syndrome, lepromatous 
leprosy, leukemia, Hodgkin's disease, polyarteritis nodosa; in patients with 
chronic renal disease on hemodialysis; and in injection drug users(17).  
Other groups with high rates of HBV infection include spouses of acutely 
infected persons, sexually promiscuous persons (especially promiscuous 
homosexual men), health care workers exposed to blood, persons who 
require repeated transfusions especially with pooled blood product 
concentrates (e.g., hemophiliacs), residents and staff of custodial institutions 
for the mentally retarded, prisoners, and, to a lesser extent, family members 
of chronically infected patients. In volunteer blood donors, the prevalence of 
anti-HBs, a reflection of previous HBV infection, ranges from 5 to 10%, but 
the prevalence is higher in lower socioeconomic strata, older age groups, 
and persons including those mentioned above exposed to blood products(8,9).    
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Hepatitis D 
  Infection with HDV has a worldwide distribution, but two epidemiologic 
patterns exist. In Mediterranean countries (northern Africa, southern Europe, 
the Middle East), HDV infection is endemic among those with hepatitis B, 
and the disease is transmitted predominantly by nonpercutaneous means, 
especially close personal contact. In nonendemic areas, such as the United 
States and northern Europe, HDV infection is confined to persons exposed 
frequently to blood and blood products, primarily injection drug users and 
hemophiliacs. HDV infection can be introduced into a population through 
drug users or by migration of persons from endemic to nonendemic areas. 
Thus, patterns of population migration and human behavior facilitating 
percutaneous contact play important roles in the introduction and 
amplification of HDV infection. Occasionally, the migrating epidemiology 
of hepatitis D is expressed in explosive outbreaks of severe hepatitis, such as 
those that have occurred in remote South American villages as well as in 
urban centers in the United States. Ultimately, such outbreaks of hepatitis D 
either of coinfections with acute hepatitis B or of superinfections in those 
already infected with HBV may blur the distinctions between endemic and 
nonendemic areas(9).   
Hepatitis C 
  Routine screening of blood donors for HBsAg and the elimination of 
commercial blood sources in the early 1970s reduced the frequency of, but 
did not eliminate, transfusion-associated hepatitis. During the 1970s, the 
likelihood of acquiring hepatitis after transfusion of voluntarily donated, 
HBsAg-screened blood was approximately 10% per patient (up to 0.9% per 
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unit transfused); 90 to 95% of these cases were classified, based on 
serologic exclusion of hepatitis A and B, as "non-A, non-B" hepatitis. For 
patients requiring transfusion of pooled products, such as clotting factor 
concentrates, the risk was even higher, up to 20 to 30%, while for those 
receiving such products as albumin and immune globulin, because of prior 
treatment of these materials by heating to 60°C or cold ethanol fractionation, 
there was no risk of hepatitis(20-22). 
In addition to being transmitted by transfusion, hepatitis C can be 
transmitted by other percutaneous routes, such as self-injection with 
intravenous drugs. In addition, this virus can be transmitted by occupational 
exposure to blood, and the likelihood of infection is increased in 
hemodialysis unit.  As a bloodborne infection, HCV potentially can be 
transmitted sexually and perinatally; however, both of these modes of 
transmission are inefficient for hepatitis C. Although 10 to 15% of patients 
with acute hepatitis C report having potential sexual sources of infection, 
most studies have failed to identify sexual transmission of this agent. The 
chances of sexual and perinatal transmission have been estimated to be 
approximately 5%, well below comparable rates for HIV and HBV 
infections(20-22).   
CLINICAL AND LABORATORY FEATURES: 
Symptoms and Signs Acute viral hepatitis occurs after an incubation 
period that varies according to the responsible agent. Generally, incubation 
periods for hepatitis A range from 15 to 45 days (mean 4 weeks), for 
hepatitis B and D from 30 to 180 days (mean 4 to 12 weeks), for hepatitis C 
from 15 to 160 days (mean 7 weeks), and for hepatitis E from 14 to 60 days 
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(mean 5 to 6 weeks). The prodromal symptoms of acute viral hepatitis are 
systemic and quite variable. Constitutional symptoms of anorexia, nausea 
and vomiting, fatigue, malaise, arthralgias, myalgias, headache, 
photophobia, pharyngitis, cough, and coryza may precede the onset of 
jaundice by 1 to 2 weeks. The nausea, vomiting, and anorexia are frequently 
associated with alterations in olfaction and taste. A low-grade fever between 
38 and 39°C (100 to 102°F) is more often present in hepatitis A and E than 
in hepatitis B or C, except when hepatitis B is heralded by a serum 
sicknesslike syndrome; rarely, a fever of 39.5 to 40°C (103 to 104°F) may 
accompany the constitutional symptoms. Dark urine and clay-colored stools 
may be noticed by the patient from 1 to 5 days before the onset of clinical 
jaundice(10,18,19).   
With the onset of clinical jaundice, the constitutional prodromal symptoms 
usually diminish, but in some patients mild weight loss (2.5 to 5 kg) is 
common and may continue during the entire icteric phase. The liver 
becomes enlarged and tender and may be associated with right upper 
quadrant pain and discomfort. Infrequently, patients present with a 
cholestatic picture, suggesting extrahepatic biliary obstruction. 
Splenomegaly and cervical adenopathy are present in 10 to 20% of patients 
with acute hepatitis. Rarely, a few spider angiomas appear during the icteric 
phase and disappear during convalescence. During the recovery phase, 
constitutional symptoms disappear, but usually some liver enlargement and 
abnormalities in liver biochemical tests are still evident. The duration of the 
posticteric phase is variable, ranging from 2 to 12 weeks, and usually is 
more prolonged in acute hepatitis B and C. Complete clinical and 
biochemical recovery is to be expected 1 to 2 months after all cases of 
 12
hepatitis A and E and 3 to 4 months after the onset of jaundice in three-
quarters of uncomplicated cases of hepatitis B and C. In the remainder, 
biochemical recovery may be delayed. A substantial proportion of patients 
with viral hepatitis never become icteric(5,13,14).   
Laboratory Features:  
 The serum aminotransferases aspartate aminotransferase (AST) and ALT 
(previously designated SGOT and SGPT) show a variable increase during 
the prodromal phase of acute viral hepatitis and precede the rise in bilirubin 
level. The acute level of these enzymes, however, does not correlate well 
with the degree of liver cell damage. Peak levels vary from 400 to 4000 IU 
or more; these levels are usually reached at the time the patient is clinically 
icteric and diminish progressively during the recovery phase of acute 
hepatitis. The diagnosis of anicteric hepatitis is difficult and requires a high 
index of suspicion; it is based on clinical features and on aminotransferase 
elevations, although mild increases in conjugated bilirubin also may be 
found.Jaundice is usually visible in the sclera or skin when the serum 
bilirubin value exceeds 43 umol/L (2.5 mg/dL). When jaundice appears, the 
serum bilirubin typically rises to levels ranging from 85 to 340 umol/L (5 to 
20 mg/dL). The serum bilirubin may continue to rise despite falling serum 
aminotransferase levels. In most instances, the total bilirubin is equally 
divided between the conjugated and unconjugated fractions. Bilirubin levels 
above 340 umol/L (20 mg/dL) extending and persisting late into the course 
of viral hepatitis are more likely to be associated with severe disease. In 
certain patients with underlying hemolytic anemia, however, such as 
glucose-6-phosphate dehydrogenase deficiency and sickle cell anemia, a 
high serum bilirubin level is common, resulting from superimposed 
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hemolysis. In such patients, bilirubin levels greater than 513 umol/L (30 
mg/dL) have been observed and are not necessarily associated with a poor 
prognosis(6,15, 20).   
Neutropenia and lymphopenia are transient and are followed by a relative 
lymphocytosis. Atypical lymphocytes (varying between 2 and 20%) are 
common during the acute phase. These atypical lymphocytes are 
indistinguishable from those seen in infectious mononucleosis. 
Measurement of the prothrombin time (PT) is important in patients with 
acute viral hepatitis, for a prolonged value may reflect a severe synthetic 
defect, signify extensive hepatocellular necrosis, and indicate a worse 
prognosis. Occasionally, a prolonged PT may occur with only mild increases 
in the serum bilirubin and aminotransferase levels. Prolonged nausea and 
vomiting, inadequate carbohydrate intake, and poor hepatic glycogen 
reserves may contribute to hypoglycemia noted occasionally in patients with 
severe viral hepatitis. Serum alkaline phosphatase may be normal or only 
mildly elevated, while a fall in serum albumin is uncommon in 
uncomplicated acute viral hepatitis. In some patients, mild and transient 
steatorrhea has been noted as well as slight microscopic hematuria and 
minimal proteinuria(20).   
A diffuse but mild elevation of the gamma globulin fraction is common 
during acute viral hepatitis. Serum IgG and IgM levels are elevated in about 
one-third of patients during the acute phase of viral hepatitis, but the serum 
IgM level is elevated more characteristically during acute hepatitis A. 
During the acute phase of viral hepatitis, antibodies to smooth muscle and 
other cell constituents may be present, and low titers of rheumatoid factor, 
nuclear antibody, and heterophil antibody also can be found occasionally. In 
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contrast, virus-specific antibodies, which appear during and after hepatitis 
virus infection, are serologic markers of diagnostic importance(1-3,8).                         
As described above, serologic tests are available with which to establish a 
diagnosis of hepatitis A, B, D, and C. Tests for fecal or serum HAV are not 
routinely available. Therefore, a diagnosis of type A hepatitis is based on 
detection of IgM anti-HAV during acute illness. Rheumatoid factor can give 
rise to false-positive results in this test. 
A diagnosis of HBV infection can usually be made by detection of HBsAg 
in serum. Infrequently, levels of HBsAg are too low to be detected during 
acute HBV infection, even with the current generation of highly sensitive 
immunoassays. In such cases, the diagnosis can be established by the 
presence of IgM anti-HBc(6,7).   
In patients with hepatitis B surface antigenemia of unknown duration, e.g., 
blood donors found to be HBsAg-positive and referred to a physician for 
evaluation, testing for IgM anti-HBc may be useful to distinguish between 
acute or recent infection (IgM anti-HBc-positive) and chronic HBV 
infection (IgM anti-HBc-negative, IgG anti-HBc-positive). A false-positive 
test for IgM anti-HBc may be encountered in patients with high-titer 
rheumatoid factor. Tests for the detection of HBV DNA in liver and serum 
are now available. 
 In patients with hepatitis C, an episodic pattern of aminotransferase 
elevation is common. A specific serologic diagnosis of hepatitis C can be 
made by demonstrating the presence in serum of anti-HCV. When a second- 
or third-generation immunoassay (that detects antibodies to nonstructural 
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and nucleocapsid proteins) is used, anti-HCV can be detected in acute 
hepatitis C during the initial phase of elevated aminotransferase activity. 
This antibody may never become detectable in 5 to 10% of patients with 
acute hepatitis C, and levels of anti-HCV may become undetectable after 
recovery from acute hepatitis C(7-9, 15,17).    
The presence of HDV infection can be identified by demonstrating 
intrahepatic HDV antigen or, more practically, an anti-HDV seroconversion 
(a rise in titer of anti-HDV or de novo appearance of anti-HDV). Circulating 
HDV antigen, also diagnostic of acute infection, is detectable only briefly, if 
at all. Because anti-HDV is often undetectable once HBsAg disappears, 
retrospective serodiagnosis of acute self-limited, simultaneous HBV and 
HDV infection is difficult. Early diagnosis of acute infection may be 
hampered by a delay of up to 30 to 40 days in the appearance of anti-
HDV(11).   
PROGNOSIS: 
Virtually all previously healthy patients with hepatitis A recover completely 
from their illness with no clinical sequelae. Similarly, in acute hepatitis B, 
95 to 99% of previously healthy adults have a favorable course and recover 
completely. There are, however, certain clinical and laboratory features that 
suggest a more complicated and protracted course. Patients of advanced age 
and with serious underlying medical disorders may have a prolonged course 
and are more likely to experience severe hepatitis. Initial presenting features 
such as ascites, peripheral edema, and symptoms of hepatic encephalopathy 
suggest a poorer prognosis. In addition, a prolonged PT, low serum albumin 
level, hypoglycemia, and very high serum bilirubin values suggest severe 
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hepatocellular disease. Patients with these clinical and laboratory features 
deserve prompt hospital admission. The case-fatality rate in hepatitis A and 
B is very low (approximately 0.1%) but is increased by advanced age and 
underlying debilitating disorders. Among patients ill enough to be 
hospitalized for acute hepatitis B, the fatality rate is 1%. Hepatitis C 
occurring after transfusion is less severe during the acute phase than 
hepatitis B and is more likely to be anicteric; fatalities are rare, but the 
precise case-fatality rate is not known. Patients with simultaneous acute 
hepatitis B and hepatitis D do not necessarily experience a higher mortality 
rate than do patients with acute hepatitis B alone; however, in several recent 
outbreaks of acute simultaneous HBV and HDV infection among injection 
drug users, the case-fatality rate has been approximately 5%. In the case of 
HDV superinfection of a person with chronic hepatitis B, the likelihood of 
fulminant hepatitis and death is increased substantially. Although the case-
fatality rate for hepatitis D has not been defined adequately, in outbreaks of 
severe HDV superinfection in isolated populations with a high hepatitis B 
carrier rate, the mortality rate has been recorded in excess of 20%(1-3,8,9,11,15).                     
COMPLICATIONS AND SEQUELAE: 
A small proportion of patients with hepatitis A experience relapsing 
hepatitis weeks to months after apparent recovery from acute hepatitis. 
Relapses are characterized by recurrence of symptoms, aminotransferase 
elevations, occasionally jaundice, and fecal excretion of HAV. Another 
unusual variant of acute hepatitis A is cholestatic hepatitis, characterized by 
protracted cholestatic jaundice and pruritus. Rarely, liver test abnormalities 
persist for many months, even up to a year. Even when these complications 
occur, hepatitis A remains self-limited and does not progress to chronic liver 
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disease. During the prodromal phase of acute hepatitis B, a serum sickness-
like syndrome characterized by arthralgia or arthritis, rash, angioedema, and 
rarely hematuria and proteinuria may develop in 5 to 10% of patients. This 
syndrome occurs before the onset of clinical jaundice, and these patients are 
often erroneously diagnosed as having rheumatologic diseases. The 
diagnosis can be established by measuring serum aminotransferase levels, 
which are almost invariably elevated, and serum HBsAg(4-6). 
The most feared complication of viral hepatitis is fulminant hepatitis 
(massive hepatic necrosis); fortunately, this is a rare event. Fulminant 
hepatitis is primarily seen in hepatitis B and D, as well as hepatitis E, but 
rare fulminant cases of hepatitis A occur primarily in older adults and in 
persons with underlying chronic liver disease. Hepatitis B accounts for more 
than 50% of fulminant hepatitis cases, a sizable proportion of which are 
associated with HDV infection. Participation of HDV can be documented in 
approximately one-third of patients with acute fulminant hepatitis B and 
two-thirds of patients with fulminant hepatitis superimposed on chronic 
hepatitis B. Fulminant hepatitis is seen rarely in hepatitis C, but hepatitis E, 
can be complicated by fatal fulminant hepatitis in 1 to 2% of all cases and in 
up to 20% of cases occurring in pregnant women. Patients usually present 
with signs and symptoms of encephalopathy that may evolve to deep coma. 
The liver is usually small and the PT excessively prolonged. The 
combination of rapidly shrinking liver size, rapidly rising bilirubin level, 
and marked prolongation of the PT, even as aminotransferase levels fall, 
together with clinical signs of confusion, disorientation, somnolence, ascites, 
and edema, indicates that the patient has hepatic failure with 
encephalopathy. Cerebral edema is common; brainstem compression, 
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gastrointestinal bleeding, sepsis, respiratory failure, cardiovascular collapse, 
and renal failure are terminal events. The mortality rate is exceedingly high 
(greater than 80% in patients with deep coma), but patients who survive may 
have a complete biochemical and histologic recovery. If a donor liver can be 
located in time, liver transplantation may be life-saving in patients with 
fulminant hepatitis(9,19).   
It is particularly important to document the disappearance of HBsAg after 
apparent clinical recovery from acute hepatitis B. Before laboratory methods 
were available to distinguish between acute hepatitis and acute hepatitis-like 
exacerbations (spontaneous reactivations) of chronic hepatitis B, 
observations suggested that approximately 10% of patients remained 
HBsAg-positive for longer than 6 months after the onset of clinically 
apparent acute hepatitis B. Half these persons cleared the antigen from their 
circulations during the next several years, but the other 5% remained 
chronically HBsAg-positive. More recent observations suggest that the true 
rate of chronic infection after clinically apparent acute hepatitis B is as low 
as 1% in normal, immunocompetent, young adults. Earlier, higher estimates 
may have been biased by inadvertent inclusion of acute exacerbations in 
chronically infected patients; these patients, chronically HBsAg-positive 
before exacerbation, were unlikely to seroconvert to HBsAg-negative 
thereafter. Whether the rate of chronicity is 10 or 1%, such patients have 
anti-HBc in serum; anti-HBs is either undetected or detected at low titer 
against the opposite subtype specificity of the antigen. These patients may 
(1) be asymptomatic carriers, (2) have low-grade, mild chronic hepatitis, or 
(3) have moderate to severe chronic hepatitis with or without cirrhosis. The 
likelihood of becoming an HBsAg carrier after acute HBV infection is 
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especially high among neonates, persons with Down's syndrome, 
chronically hemodialyzed patients, and immunosuppressed patients, 
including persons with HIV infection.Chronic hepatitis is an important late 
complication of acute hepatitis B(4-7).    
After transfusion-associated acute hepatitis C, at least 50% of patients have 
abnormal biochemical liver tests for more than a year. In some experiences, 
the frequency of progression to chronicity after acute hepatitis C is as high 
as 70%. In most of these patients, liver histology is consistent with moderate 
to severe chronic hepatitis. Thus, after acute HCV infection, the likelihood 
of remaining chronically infected approaches 85 to 90%. Although many 
patients with chronic hepatitis C have no symptoms, cirrhosis may develop 
in as many as 20% within 10 to 20 years of acute illness; in some series of 
cases, cirrhosis has been reported in as many as 50% of patients with 
chronic hepatitis C. In contrast, neither HAV nor HEV causes chronic liver 
disease(1,2,12-14,20-22).  
Rare complications of viral hepatitis include pancreatitis, myocarditis, 
atypical pneumonia, aplastic anemia, transverse myelitis, and peripheral 
neuropathy. Carriers of HBsAg, particularly those infected in infancy or 
early childhood, have an enhanced risk of hepatocellular carcinoma. The risk 
of hepatocellular carcinoma is increased as well in patients with chronic 
hepatitis C, almost exclusively in patients with cirrhosis, and almost always 
after at least several decades, usually after three decades of disease). In 
children, hepatitis B may present rarely with anicteric hepatitis, a nonpruritic 
papular rash of the face, buttocks, and limbs, and lymphadenopathy(18,19,23).  
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TREATMENT: 
Treatment of Acute Attack Although therapy has been developed for chronic 
hepatitis B and C, opportunities for treating acute hepatitis caused by HBV 
or HCV are limited. In hepatitis B, among previously healthy adults who 
present with clinically apparent acute hepatitis, recovery occurs in 
approximately 99%; therefore, antiviral therapy is not likely to improve the 
rate of recovery and is not required. In rare instances of severe acute 
hepatitis B, treatment with a nucleoside analogue, such as lamivudine, at the 
100-mg/d oral dose used to treat chronic hepatitis B. has been attempted 
successfully. However, clinical trials have not been done to establish the 
efficacy of this approach, severe acute hepatitis B is not an approved 
indication for therapy, and the duration of therapy has not been determined. 
In typical cases of acute hepatitis C, recovery is rare, progression to chronic 
hepatitis is the rule, occurring in 85 to 90% of patients, and meta-analyses of 
small clinical trials suggest that antiviral therapy with interferon alpha (3 
million units subcutaneously three times a week) is beneficial, reducing the 
rate of chronicity considerably by inducing sustained responses in 40% of 
patients. The duration of therapy and whether to add the nucleoside 
analogue ribavirin remain to be determined, but the most reasonable 
approach is to follow recommendations for treatment of chronic hepatitis C. 
Because of the marked reduction over the last two decades in the frequency 
of acute hepatitis C, opportunities to identify and treat patients with acute 
hepatitis C are rare indeed. Hospital epidemiologists, however, will 
encounter health workers who sustain hepatitis C-contaminated needle 
sticks; when monitoring for ALT elevations and HCV RNA after these 
accidents identifies acute hepatitis C, therapy should be initiated(20,24,25).  
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Notwithstanding these specific therapeutic considerations, in most cases of 
typical acute viral hepatitis, specific treatment generally is not necessary. 
Although hospitalization may be required for clinically severe illness, most 
patients do not require hospital care. Forced and prolonged bed rest is not 
essential for full recovery, but many patients will feel better with restricted 
physical activity. A high-calorie diet is desirable, and because many patients 
may experience nausea late in the day, the major caloric intake is best 
tolerated in the morning. Intravenous feeding is necessary in the acute stage 
if the patient has persistent vomiting and cannot maintain oral intake. Drugs 
capable of producing adverse reactions such as cholestasis and drugs 
metabolized by the liver should be avoided. If severe pruritus is present, the 
use of the bile salt-sequestering resin cholestyramine will usually alleviate 
this symptom. Glucocorticoid therapy has no value in acute viral hepatitis. 
Even in severe cases associated with bridging necrosis, controlled trials 
have failed to demonstrate the efficacy of steroids. In fact, such therapy may 
be hazardous(20,25). 
In fulminant hepatitis, the goal of therapy is to support the patient by 
maintenance of fluid balance, support of circulation and respiration, control 
of bleeding, correction of hypoglycemia, and treatment of other 
complications of the comatose state in anticipation of liver regeneration and 
repair. Protein intake should be restricted, and oral lactulose or neomycin 
administered. Glucocorticoid therapy has been shown in controlled trials to 
be ineffective. Likewise, exchange transfusion, plasmapheresis, human 
cross-circulation, porcine liver cross-perfusion, and hemoperfusion have not 
been proven to enhance survival. Meticulous intensive care is the one factor 
that does appear to improve survival. Orthotopic liver transplantation is 
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resorted to with increasing frequency, with excellent results, in patients with 
fulminant hepatitis(19).   
PROPHYLAXIS: 
Because application of therapy for acute viral hepatitis is limited, and 
because antiviral therapy for chronic viral hepatitis is effective in only a 
proportion of patients emphasis is placed on prevention through 
immunization. The prophylactic approach differs for each of the types of 
viral hepatitis. In the past, immunoprophylaxis relied exclusively on passive 
immunization with antibody-containing globulin preparations purified by 
cold ethanol fractionation from the plasma of hundreds of normal donors. 
Currently, for hepatitis A and B, active immunization with vaccines is 
available as well(23).   
Hepatitis A  
 Both passive immunization with immune globulin (IG) and active 
immunization with a killed vaccine are available. All preparations of IG 
contain anti-HAV concentrations sufficient to be protective. When 
administered before exposure or during the early incubation period, IG is 
effective in preventing clinically apparent hepatitis A. For postexposure 
prophylaxis of intimate contacts (household, institutional) of persons with 
hepatitis A, the administration of 0.02 mL/kg is recommended as early after 
exposure as possible; it may be effective even when administered as late as 
2 weeks after exposure.  
Hepatitis A vaccines are approved for use in persons who are at least 2 years 
old and appear to provide adequate protection 4 weeks after a primary 
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inoculation. If it can be given within 4 weeks of an expected exposure, such 
as by travel to an endemic area, hepatitis A vaccine is the preferred approach 
to preexposure immunoprophylaxis. If travel is more imminent, IG (0.02 
mL/kg) should be administered at a different injection site, along with the 
first dose of vaccine. Because vaccination provides long-lasting protection 
(protective levels of anti-HAV should last 20 years after vaccination), 
persons whose risk will be sustained (e.g., frequent travelers or those 
remaining in endemic areas for prolonged periods) should be vaccinated, 
and vaccine should supplant the need for repeated IG injections(23,26,28).  
Hepatitis B  
For preexposure prophylaxis against hepatitis B in settings of frequent 
exposure (health workers exposed to blood, hemodialysis patients and staff, 
residents and staff of custodial institutions for the developmentally 
handicapped, injection drug users, inmates of long-term correctional 
facilities, promiscuous homosexual men as well as promiscuous 
heterosexual individuals, persons such as hemophiliacs who require long-
term, high-volume therapy with blood derivatives, household and sexual 
contacts of HBsAg carriers, persons living in or traveling extensively in 
endemic areas, unvaccinated children under the age of 18, and unvaccinated 
children who are Alaskan natives, Pacific Islanders, or residents in 
households of first-generation immigrants from endemic countries), three 
intramuscular (deltoid, not gluteal) injections of hepatitis B vaccine are 
recommended at 0, 1, and 6 months. Pregnancy is not a contraindication to 
vaccination. postexposure prophylaxis with a combination of HBIG (for 
rapid achievement of high-titer circulating anti-HBs) and hepatitis B vaccine 
(for achievement of long-lasting immunity as well as its apparent efficacy in 
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attenuating clinical illness after exposure) is recommended. The precise 
duration of protection afforded by hepatitis B vaccine is unknown; however, 
approximately 80 to 90% of immunocompetent vaccinees retain protective 
levels of anti-HBs for at least 5 years, and 60 to 80% for 10 years. Currently, 
booster immunizations are not recommended routinely, except in 
immunosuppressed persons who have lost detectable anti-HBs or 
immunocompetent persons who sustain percutaneous HBsAg-positive 
inoculations after losing detectable antibody. Specifically, for hemodialysis 
patients, annual anti-HBs testing is recommended after vaccination; booster 
doses are recommended when anti-HBs levels fall below 10 mIU/mL(23,29-32).   
Hepatitis D  
 Infection with hepatitis D can be prevented by vaccinating susceptible 
persons with hepatitis B vaccine. No product is available for 
immunoprophylaxis to prevent HDV superinfection in HBsAg carriers; for 
them, avoidance of percutaneous exposures and limitation of intimate 
contact with persons who have HDV infection are recommended(23).   
 
Hepatitis C  
 IG is ineffective in preventing hepatitis C and is no longer recommended 
for postexposure prophylaxis in cases of perinatal, needle stick, or sexual 
exposure. Although a prototype vaccine that induces antibodies to HCV 
envelope protein has been developed, currently, hepatitis C vaccination is 
not feasible practically. Genotype and quasispecies viral heterogeneity, as 
well as rapid evasion of neutralizing antibodies by this rapidly mutating 
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virus, conspire to render HCV a difficult target for immunoprophylaxis with 
a vaccine.  
For stable, monogamous sexual partners, sexual transmission of hepatitis C 
is unlikely, and sexual barrier precautions are not recommended. For 
persons with multiple sexual partners or with sexually transmitted diseases, 
the risk of sexual transmission of hepatitis C is increased, and barrier 
precautions (latex condoms) are recommended. A person with hepatitis C 
should avoid sharing such items as razors, toothbrushes, and nail clippers 
with sexual partners and family members. No special precautions are 
recommended for babies born to mothers with hepatitis C, and breast 
feeding does not have to be restricted(23,24,31, 33-37).   
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HEPATITIS   E VIRUS INECTION 
 Hepatitis E virus ( HEV) is self limited virus , enterically_ transmitted acute 
viral hepatitis . In the winter of 1955-56, a large epidemic of acute viral 
hepatitis, affecting 29 000 people, followed an incident of sewage 
contamination of drinking water in New Delhi, India. Although it was 
originally considered to be an epidemic of hepatitis A, retrospective testing 
of stored sera from these patients suggested that a novel infectious agent was 
responsible for the epidemic. This disease, which was initially described 
from the Indian subcontinent, was first called enteric non-A, non-B hepatitis 
(ET-NANBH). Since the early 1990s, following the identification and 
sequencing of its aetiological agent, the disease became known as hepatitis E 
and its agent as hepatitis E virus (HEV) (20,38).    
THE VIRUS:- 
 HEV is a spherical non-enveloped, RNA virus that is approximately 32-34 
nm in diameter (Fig1). Structurally similar to virus of the Caliciviradae 
family. The viral genome has been cloned and sequenced from several 
geographically distinct HEV isolates and shows a high degree of sequence 
conservation, both of nucleotides and of amino acids(2,3). The HEV genome 
is an +RNA of ~7.5 kb, spanning a coding region that includes three open 
reading frames (ORFs) (39-44).    
1 The largest ORF consist of 1693 codons, it codes for nonstructural 
proteins that are responsible for the processing and replication of the 
virus. 
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2 The second ORF is composed of 660 codons, cods for structural 
proteins. 
3 The third ORF consist of 123 codons, its function remains 
undetermined. 
 
Figure A. Hepatitis E virus. An immunoelectron micrograph of hepatitis E 
virus (HEV) from the stool of a patient acutely infected with the Burmese 
isolate. The picture shows 27–34 nm particles aggregated with antibodies 
present in the serum of a patient infected with HEV. Obtained from the viral 
hepatitis slide set published by the US Centers of Disease Control and 
Prevention, Atlanta, GA, USA  
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Epidemiology of hepatitis E:- 
HEV causes epidemics of viral hepatitis, often involving very large numbers 
of patients. Such epidemics have been reported from several countries on all 
continents, although most are in tropical and subtropical areas of the world 
(Ref. 8). Apart from the 1955-56 New Delhi epidemics, other notable 
epidemics have occurred: Kirgiz Republic, Soviet Union (1955-56, 10 000 
cases); Kathmandu Valley, Nepal (1973-74, 10 000 cases); Mandalay, 
Myanmar (1976-77, 20 000 cases); Kashmir, India (1978-82, 52 000 cases); 
Xinjiang, China (1986-88, 120 000 cases); and Kanpur, India (1991, 79 000 
cases). In addition to epidemic hepatitis, HEV causes rampant sporadic 
infections in endemic areas of  more than 25% of sporadic non-ABC 
hepatitis cases are due to HEV infection. In India, for example, ~30% of all 
sporadic viral hepatitis is due to infection by HEV(45).   
HEV is transmitted primarily through the faecal-oral route in contaminated 
drinking water (45). The disease is found most frequently in geographical 
regions and situations, such as refugee camps, where faecal contamination of 
the drinking water supply is frequent. Although they have only minor 
contributions, other routes of transmission cannot be ruled out. For example, 
vertical transmission in uterus of HEV from infected mothers to their 
newborn has been documented (46). The possibility of parenteral transmission 
has also been suggested, especially in endemic areas. However, person-to-
person transfer is minimal because household contacts of HEV-infected 
patients do not appear to be at an increased risk(47).   
As expected, the seroprevalence of anti-HEV antibodies in endemic areas is 
significantly higher than in areas where HEV infection is rare. Acute 
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hepatitis E has been reported in patients residing in developed countries such 
as Australia, France, Israel, The Netherlands, Spain, UK and USA. These are 
mainly associated with travel to endemic areas (45); however, rare cases of 
acute hepatitis E have also been reported from these regions in the absence 
of travel to risk areas. HEV infection is also probably more prevalent in 
industrialized nations than previously appreciated; for example, fulminant 
HEV-associated hepatitis is found in Europe, where ~1.5% of healthy adults 
have anti-HEV antibodies (48). In addition, in the USA, domesticated swine 
have been found to be infected with HEV, and sequence analysis has shown 
that swine-derived HEV is similar to a human-derived HEV from a USA 
isolate (49). 
The age-specific prevalence of anti-HEV antibodies has also been studied in 
endemic areas and compared with antibodies to HAV.   Whereas anti-HAV 
seroprevalence reaches >95% by 10 years of age in endemic areas, anti-HEV 
seroprevalence in an identical population slowly increases until the third 
decade of life. This pattern suggests a sporadic transmission of the virus that, 
the short periods of infectious viraemia (virus in the bloodstream), and the 
consequently limited accumulates over age; this is consistent with the 
predominantly sub clinical nature of infections pool of HEV infection in the 
community. Lower prevalence rates of anti-HEV versus anti-HAV 
antibodies in the same population also suggests that, following infection, 
antibodies to HEV might disappear from circulation faster than antibodies to 
HAV, and that children might not mount such a brisk anti-HEV antibody 
response compared with that mounted by adults.  
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However, these issues remain unresolved, owing mainly to the lack of 
sensitive and specific diagnostic systems that are suitable for use in endemic 
areas(50).  
Time course of hepatitis E virus infection: 
 
Figure B. Time course of hepatitis E virus infection. Biochemical markers (e.g. serum 
ALT levels) and symptomatic markers (e.g. jaundice) of viral hepatitis are correlated with 
detection of HEV RNA by RT-PCR in the bloodstream, or shedding of virus in stools, 
and the immune response is measured as anti-HEV IgM or IgG levels, detected by 
enzyme immunoassay on serum samples. Four to eight weeks after exposure to HEV, 
there is a rise in ALT and the appearance of jaundice. Immediately prior to the onset of 
clinical symptoms, HEV can be detected in the bloodstream for ~1–2 weeks and is shed 
in the stools for ~3–4 At the onset of clinical symptoms, HEV is lost from the 
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bloodstream, but continues to be shed in stools. Anti-HEV IgM and IgG titres continue to 
increase in the asymptomatic phase. The anti-HEV IgM titre peaks during the 
symptomatic phase and declines thereafter to baseline values within 3–6 months of 
symptomatic disease. The anti-HEV IgG titre remains detectable for 2–13 years as 
determined in various studies (published by the US Centers of Disease Control and 
Prevention, Atlanta, GA, USA) 
Hepatitis Pathogenesis and clinical spectrum of E:- 
Although the hepatitis viruses cause liver damage, none is directly 
cytopathic to hepatocytes (liver cells). Following acute liver injury, the 
clinical manifestations and outcome of viral hepatitis are actually determined 
by the host immune response. Because serological (antibody-based) assays 
for HEV have only recently become available, the pathogenesis of hepatitis 
E is not well understood. Following the entry of HEV into the host via the 
oral route, the primary site of replication is probably in the intestinal tract. It 
is still not clear how the virus reaches the liver, but it is presumably via the 
portal vein serving the liver. HEV replicates in the cytoplasm of hepatocytes  
and is released into the bile and bloodstream by mechanisms that are not 
understood(51).   
 The symptoms of hepatitis E are typical of acute viral hepatitis and the 
infection follows a natural history that is similar to that of hepatitis A. 
Jaundice is usually accompanied by malaise , nausea . vomiting, abdominal 
pain ,fever, and hepatomegaly. Other less common feature include diarrhea ,  
artharalgia , pruritus and urticarial rash(51).   
The incubation period (the time from infection to clinical symptoms) has 
been measured accurately only in a single case of transmission of HEV to a 
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human volunteer, and was found to be 32 days(52).    
 Infectious viral particles are present in the bile and faeces during the late 
incubation phase of hepatitis E and they persist for a week or two following 
the onset of clinical disease. The virus is also present transiently in the 
bloodstream in the late incubation phase of hepatitis E, but it disappears just 
before the onset of clinical symptoms(52) Anti-HEV antibodies of the IgA, 
IgG and IgM types appear during the course of disease. IgM antibodies are 
detectable in the acute phase and disappear in 3-6 months whereas, in 
various studies, IgG antibodies have been shown to persist for 2-13 years (45). 
 In ~10% of patients with HEV infection, protracted viraemia has been 
observed in the absence of anti-HEV antibodies (seroconversion). 
Seroconversion might be a critical marker for early clearance of the virus 
from the bloodstream, but this requires more extensive analysis. In most 
hepatitis E outbreaks, the highest rates of clinically evident disease have 
been reported in young to middle-age adults; the lower disease rates in 
younger age groups might be the result of anicteric (i.e. without the 
elevation of serum bilirubin that is used as a marker of clinical jaundice) 
and/or sub clinical HEV infection (53).    
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  Hepatitis E in pregnancy  :-         
One distinctive clinical feature of hepatitis E, compared with other forms of 
viral hepatitis, is its increased incidence and severity in pregnant women(54) 
which results in up to 20% mortality. By contrast, none of the other 
recognized hepatitis viruses causes such severe hepatitis in pregnancy. 
Though the mechanism(s) is not known, a hypothesis has been put forward 
to explain the pathogenesis of fulminant hepatitis E in pregnancy(55).   
 This suggests that the liver sinusoidal cells, particularly the Kupffer cells, 
are damaged by HEV, which diminishes the ability of these cells to protect 
hepatocytes against endotoxins that originate from Gram-negative bacteria 
found in the intestinal tract. Hepatocytes can be injured directly by 
endotoxins or indirectly by eicosanoids, which are 20-carbon chain (C20) 
polyunsaturated fatty acids that cause platelet aggregation, inflammation, 
and other effects. Release of prostaglandins (a type of eicosanoid) can lead 
to chemotactic attraction of inflammatory neutrophils. This can result in 
swelling of the tissue by water accumulation (oedema) and arrest of bile 
flow (cholestasis). The enhanced sensitivity of pregnant women to such an 
endotoxin-mediated effect is well recognised and might explain the 
strikingly high mortality of hepatitis E in pregnancy. However, the validity 
of this hypothesis and the precise cellular/molecular mechanisms underlying 
it have not been confirmed(55).    
The kidneys of cynomolgus monkeys (Macaca fascicularis) infected 
intravenously with HEV were shown to develop acute tubular necrosis with 
focal haemorrhages, suggesting that HEV can replicate in monkey (and 
possibly also human) kidneys. By affecting this tissue, HEV might 
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precipitate pregnancy-associated eclampsia, leading to increased mortality in 
pregnant women. One feature observed in patients with eclampsia is 
disseminated intravascular coagulation affecting the liver and kidneys. In 
pregnant women, a high incidence of disseminated intravascular coagulation 
associated with hepatitis E is well recognised. However, in experimental 
HEV infection of pregnant monkeys, no increased mortality has been 
observed, casting doubt on whether this is a good model for this aspect of 
human hepatitis E(56).   
Liver histology of patients with hepatitis E reveals portal triaditis, 
cholestasis, lobular inflammation and degeneration of the liver to varying 
degrees, which are all suggestive of acute viral hepatitis. However, nearly 
half of the patients have distinctive morphological changes designated as 
cholestatic viral hepatitis. The discrepancy between the time of appearance 
of viral replication in the liver with the histopathological and biochemical 
changes suggests that HEV might not be directly cytopathic and its 
pathogenesis might be immunologically mediated(57).    
Other study shows existence of a Th2 bias in pregnant women with acute 
hepatitis E, but The role of this Th2 bias in the greater severity of hepatitis E 
among pregnant women needs further investigation(58).   
It is not known whether HEV causes other sequelae or extrahepatic 
manifestations. None has been recognised apart from the increased incidence 
of miscarriage, which has been reported in some, but not all, studies on 
fulminant hepatitis E during pregnancy(56).   
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Diagnostic tests for HEV:- 
Only one serological test to diagnose HEV infection is commercially 
available (Genelabs Technologies, Singapore). They do  a comparison of a 
new immunochromatographic test to enzyme-linked immunosorbent assay 
for rapid detection of immunoglobulin m antibodies to hepatitis e virus in 
human. This study showed that this test was able to detect anti-HEV IgM 
antibodies in 96.7% of the patient samples tested (n = 151) while 
maintaining an excellent  rapid test gave a good specificity of 90.9% when 
tested with rheumatoid factor (RF)-positive sera (RF value of < or =850 
IU/ml; n = 11) although a higher concentration of RF in samples might cause 
cross-reactivity. The new test has a good agreement of 97.2% with a kappa 
value of 0.943 when compared with a reference enzyme-linked 
immunosorbent assay. The positive predictive value and the negative 
predictive value for the rapid test thus reached 98.0 and 97.6%, respectively. 
This is the first rapid, point-of-care test for hepatitis E and will be especially 
useful for the diagnosis of acute hepatitis E virus infection in field and 
emergency settings and in resource-poor countries(58).   
However, several diagnostic tests are available in research laboratories, 
including: 
 (1) EIAs and western blot assays to detect anti-HEV IgM and IgG in 
serum(59).   
 (2) PCR tests to detect HEV RNA in sera and stools  
(3) immunofluorescent antibody-blocking assays to detect antibody to HEV 
antigen in the serum and in liver biopsies. However, the sensitivity and 
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specificity of these tests have not been determined independently using a 
good panel of anti-HEV positive and negative sera(60).   
-:Prevention  
No products are currently available to prevent hepatitis E. Passive 
immunization using immunoglobulins prepared from plasma collected from 
HEV-infected persons in non-HEV-endemic areas is not effective in 
preventing clinical disease during hepatitis E outbreaks, and the efficacy of 
immunoglobulins prepared from plasma collected in HEV-endemic areas is 
also unclear. In studies with prototype anti-HEV vaccines in animals, 
vaccine-induced antibody could attenuate HEV infection but did not prevent 
virus excretion in the stools of infected immunised animals(61).   
For viral pathogens that are difficult to culture and therefore not easily 
amenable to the development of live attenuated strains, a promising 
approach is to develop subunit vaccines. A subunit vaccine consists of a part 
of the virus, typically a protein capable of generating a protective immune 
response in immunised persons. Recombinant DNA technology is now 
routinely used to generate large amounts of purified viral proteins to be used 
as subunit vaccines. For HEV, the most promising subunit vaccine candidate 
so far appears to be the ORF2-encoded protein when expressed in insect 
cells using recombinant baculoviruses (60).. Recently, the products of N-
terminally truncated ORF2 were shown to form empty virus-like particles 
(VLPs) (61). These VLPs retain native virus epitopes and appear to be a good 
vaccine candidate(62).   
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Alternative strategies for developing anti-HEV vaccines are also being tried 
in research laboratories. A naked DNA immunisation approach in which 
ORF2 was injected as an expression plasmid directly into muscle resulted in 
moderate anti-pORF2 titres in mice. Within days of ORF2 plasmid DNA 
injection, the subsequent injection of genes encoding either of the 
immunomodulatory cytokines interleukin 2 (IL-2) or granulocyte–monocyte 
colony-stimulating factor (GM-CSF) resulted in higher anti-pORF2 titres in 
mice (R. Tuteja and S. Jameel, unpublished). Naked DNA immunization 
with ORF2 expression vectors has also been tried in macaques, with 
promising results (S. Kamili and K. Krawczynski, unpublished). Other 
strategies such as the expression of ORF2 in bacille Calmette–Guérin (BCG) 
recombinant mycobacteria or in transgenic plant expression systems are also 
being tried. If successful, these might lead to oral or edible vaccines to 
prevent enteric infection by HEV(60).   
Therapeutic approaches to hepatitis E infection:- 
 No therapeutic compounds against hepatitis E are currently available; the 
only treatments are supportive in nature. Possible drug targets include the 
HEV Pr and RdRp enzymes, on which even the basic biochemical 
information is not yet available. Such information will be critical for 
developing assays to screen libraries of natural or synthetic molecules to 
search for compounds with anti-HEV activity. The HEV RNA 5' and 3' ends 
appear to interact with viral and cellular proteins and are crucial for its 
replication; strategies designed to block these interactions, for example with 
antisense oligonucleotides, ribozymes or small molecules, might be of 
therapeutic value. No information is available as to whether any of these 
approaches are currently being employed(61).   
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STUDY OBJECTIVES  
 
Main objective: 
 
• To determine the prevalence of hepatitis E in acute hepatitis in 
Sudanese patient presenting to Khartoum Teaching Hospital. 
 
Specific objective: 
 
• To identify the clinical presentation and complication of hepatitis E. 
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MATERIALS AND METHODS 
 
Study design: 
This is a hospital based cross-sectional study, carried out in Khartoum 
teaching hospital in the period between October 2004 to April 2005. 
Study population were male and females aged >15 years with acute 
hepatitis, proved by investigations. 
Inclusion criteria: 
• Patient with acute hepatitis. 
• Patients age > 15 years. 
Exclusion criteria: 
• Patients with chronic liver disease. 
• Patients with obstructive jaundice. 
• Patients with haemolytic jaundice.  
Data collection: 
Coded, standard questionnaires we used for interview and was filled by 
researcher and other medical personnel (House officer, medical officer, 
medical registrar). History was taken from the patients or their relatives.  
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A blood sample was drown for analysis, all patient who agree to be included 
in the study underwent the following tests. 
1- Hb%. 
2- Reticulocytes count. 
3- TWBC. 
4- S. billirubin. 
5- S. ALP. 
6- S. ALT. 
7- S. AST. 
8- U/S abdomen. 
When patients proved to have acute hepatitis, further investigation then were 
carried out:- 
1- HEV IgM. 
2- HEV IgG. 
3- HBAg. 
4- HCV  Ab. 
5- HAV  IgM. 
Technical data: 
Genlabs diagnostic (GLD) HEV IgM Elisa which is an enzyme linked 
immunosurbant assay intended for detection of IgM antibodies to hepatitis E 
virus, this kits were used in the study. 
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Serum sample was taken and stored below – 20ºC .10 microgram then taken 
and diluted 1:21 with sample buffer; then incubated for 30 minute at 37ºC. 
This test has sensitivity of 93% and specifity of 97.5%. 
Data entry and analysis: 
Were done using SPSS and conducted by four independent persons results 
will be express in the form of figure, table and graft.    
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RESULTS 
This is a cross-sectional study conducted over 6 months in Khartoum 
Teaching Hospital, 50 patients with acute hepatitis were studied, 11 of them 
were found to have hepatitis E IgM antibodies (22%), 9 of them have 
hepatitis E virus IgG antibodies. 11 patients have hepatitis B sAg (22%),4 
patients  have hepatitis c virus antibodies (8%) and 2 patents have hepatitis 
A IgM antibodies(4%). (Figure 1). 
Males are found to be more affected than females (63%). (Figure 2) 
In this study hepatitis E is found to affect all age groups but more common 
between 26 -45 year old (54%).(Table 1). 
Most patients in the study came from central Sudan (63%), no patient from 
the north or south (Figure 3).  
Educational level of the studied patients revealed that 54% of them have 
primary school level, 27% have secondary school level and 8% have 
university degree (Figure 4). 
Most of studied patients were of low socioeconomic status (54.5%)          
(Figure 5).   
In our study all patients were jaundiced and had nausea & vomiting (100%), 
(90.9%) had fever (pv= 0.148), (81%) had abdominal pain (pv= 0.986 not 
statistically significant).(Figure 6) 
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4 patients in the study have past history of jaundice (36.4%  pv= o.oo6), no 
patients has history of blood transfusion (Table 2) 
Physical examination of the studied patients revealed that 5 patients have 
enlarged liver (45.5%), 1 patient have enlarged spleen (9.1%) and 2 patients 
have enlarge liver & spleen (18.2%) and 3 patients have normal liver & 
spleen (27.3%) pv=0.07.(Table 3) 
Two patients presented with fulminant hepatic failure and they died (18%) 
pv=0.126not statistically significant (Figure 7). 
All patents have high billurbin (Table 4), have a high transaminase  specially 
those presented with fulminant hepatic failure (Table 5,6,7).   
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Table (1):  
The age distribution of 11 patients with H.E.V presenting to K.T.H in a 
period  between October 2004 to April 2005  
Age group Frequency Percentage 
15 – 25 1 9.1% 
26 – 35 1 9.1% 
36 – 45 6 54.5% 
> 45 3 27.3% 
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Table (2): 
Past history of jaundice and blood transfusion in 11 patients with 
hepatitis E in presenting to K.T.H in a period  between October 2004 to 
April 2005  
 Frequency Percentage 
Blood transfusion  0 0% 
Jaundice  4 36.4% 
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Table (3): 
Distribution of enlarged liver and spleen in 11 patients with hepatitis E 
in presenting to K.T.H in a period between October 2004 to April 2005  
 Frequency Percentage 
Enlarged live  5 45.5% 
Enlarged spleen 1 9.1% 
Enlarged  liver & spleen 2 18.2% 
Normal liver & spleen 3 27.3% 
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Table (4): 
The levels of bilirubin in 11 patients with hepatitis E in presenting to 
K.T.H in a period between October 2004 to April 2005  
Bilirubin mg/dl  Frequency Percentage 
5.20 1 9.1% 
5.24 1 9.1% 
7.80 1 9.1% 
9.70 1 9.1% 
10.00 1 9.1% 
11.00 1 9.1% 
11.50 1 9.1% 
12.00 1 9.1% 
15.00 1 9.1% 
15.50 1 9.1% 
27.80 1 9.1% 
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Table (5): 
The levels of AST in 11 patients with hepatitis E in presenting to K.T.H 
in a period between October 2004 to April 2005  
AST  U/L Frequency Percentage 
60.00 1 9.1% 
76.00 1 9.1% 
104.00 1 9.1% 
150.00 1 9.1% 
320.00 1 9.1% 
330.00 2 18.2% 
494.00 1 9.1% 
570.00 1 9.1% 
600.00 1 9.1% 
655.00 1 9.1% 
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Table (6): 
The levels of ALT in 11 patients with hepatitis E in presenting to K.T.H 
in a period between October 2004 to April 2005  
ALT     U/L Frequency Percentage 
55.00 1 9.1% 
70.00 1 9.1% 
88.00 1 9.1% 
110.00 1 9.1% 
228.00 1 9.1% 
277.00 1 9.1% 
532.00 1 9.1% 
597.00 1 9.1% 
660.00 1 9.1% 
750.00 1 9.1% 
787.00 1 9.1% 
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Table (7): 
The relationship between acute fulminant hepatic failure and 
transaminase level and bilirubin in 11 patients with hepatitis E in 
presenting to K.T.H in a period between October 2004 to April 2005  
 AST    U/L ALT    U/L Bilirubin mg/dl 
Patient 1 600 750 15.5 
Patient 2 655 787 27.8 
 
 
 
 
 
 
 
 
 
 
 
 51
Figure (1): Prevalence of hepatitis E in 50 patients with 
acute hepatitis presenting of K.T.H between October 2004 - 
April 2005
22%
4%
8%
22%
44%
HEV HAV HCV HBV Others
51
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 52
Figure (2): Distribution of sex in 11 patients with hepatitis 
E presenting to K.T.H between October 2004 - April 2005
63.40%
36.60%
Male Female
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Figure (3): Resident distribution of 11 patients with 
hepatitis E presenting K.T.H between October 2004 - April 
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Fgure (4): Distribution of educational level of 11 patients 
with hepatitis E presenting K.T.H between October 2004 - 
April 2005
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Figure (5): Distribution of socioeconomic status of 11 
patients with hepatitis E presenting K.T.H between October 
2004 - April 2005
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Figure (6): Distribution of presenting symptoms  of 11 
patients with hepatitis E presenting K.T.H between October 
2 4 - April 2005
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Figure (7): Distribution of fulminant hepatic failure of 11 
patients with hepatitis E presenting K.T.H between October 
2004 - April 2005
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DISCUSSION  
Hepatitis E infection is self-limited disease. The virus is entrically 
transmitted. It is a major cause of viral hepatitis in many of the developing 
countries, where it causes sporadic and epidemic infection. 
This study show the prevalence of hepatitis E in 50 patients with acute 
hepatitis is 22%, it is different from study done in Khartoum during the 1988 
shows when there was epidemic of acute hepatitis, 55 patients were screened 
for hepatitis E virus IgM and hepatitis E virus IgG, 58% found to have IgM 
positive and 29 patients found to have IgG (63).  Other study done in 1991 – 
1992 in acute sporadic hepatitis E in Sudanese children was found that the 
prevalence was 59% (64). 
Male are found to be more affected than females (1.8 : 1), the 
commonest age group between 26-45, this result is similar to that obtained in 
Kathmandu, Vally, Nepal during 1981 – 1982, which revealed that 75% of 
patient were male and the age affect between 15 – 36 (ref 62), and also 
similar to the result of the study done during 1988 floods in Khartoum – 
Sudan which revealed male patient is 85% in the average age between 3-48 
(63). 
Most of the affected patients were of low socioeconomic status and 
not educated, this is in keeping with literature where the diseases is found in 
refuge camps, with bad hygiene and over crowded (43). 
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The study show there is no difference in clinical presentation of 
hepatitis E and other hepatitis (65). 
There is a high incidence of fulminant hepatic failure in hepatitis E 
which lead to all case fertility (18%). This is different from reported study 
from East Africa and Asia which revealed mortality rate of 0.5 – 3% and 
high mortality in pregnant lady 20% (66). This may be due to small number of 
patients in the study. 
Hepatitis E is commoner than hepatitis A in the studied group. There 
is no co-infection with hepatitis B or hepatitis C. This is similar to the 
previous study (63). 
The serological provide of hepatitis E in these found in the study 
suggest that the IgG antibody response appears early in this infection, this is 
similar to previous study (63).  
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CONCLUSION  
 
• The study show high prevalence of hepatitis E infection among patient 
presented with acute hepatitis. 
• There is high incidence of fulminant hepatic failure and death in 
patient with hepatitis E in studied group. 
• Hepatitis E is more common in males. 
• Hepatitis E is more common in age group 26 – 45.  
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RECOMMENDATIONS 
 
• Further larger study is needed to know more about hepatitis E in 
Sudan. 
• Increase doctor awareness of the existence of hepatitis E in Sudan and 
it’s possible sequences. 
• Improve sanitation, personal hygiene, avoiding drinking water of 
unknown purity to prevent hepatitis E infection. 
• HEV IgM Elisa test should be made available in local laboratories.       
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University of Khartoum 
Faculty of Medicine 
Questionnaire 
On prevalence of HEV in acute hepatitis in Sudanese patients in period 
between October 2004 – April 2005 
1- Demographic data: 
1.1. Name………………………………………………………………… 
1.2. Sex:      Male  Female 
1.3. Age: 15-25yrs  25-35yrs     35-45yrs        >45yrs 
1.4. Residence: East     West  Central  North  South 
1.5. Occupation: Laborer  Professional  Government employee 
Military      Business  Others 
1.6. Educational level: Illiterate  Primary Secondary 
University  Higher level 
1.7. Socioeconomic level: Low  Moderate          High 
2- History: 
present symptom: 
2.1. Yellowish discoloration of the sclera: Yes  No       Duration 
2.2. Fever:       Yes  No       Duration 
2.3. Nausea & vomiting:     Yes  No       Duration 
2.4. Abdominal pain:     Yes  No       Duration 
Past history:   Blood transfusion   Jaundice 
3- Physical examination: 
3.1. Pale :   Yes  No        
3.2. Jaundice:  Yes  No        
3.3. Abdomen 
 Liver  Normal  Abnormal   Specify……………. 
 Spleen Normal  Abnormal   Specify……………. 
3.4. Other systems  Normal     Abnormal 
Specify……………………………………………………………………
…………………………………………………………………………… 
 2
4- Investigation: 
Haematology: 
 Hb%…………………….. 
 Retics……………………. 
 TWBCs………………….. 
Liver function test: 
 Billirubin………………… 
 ALP……………………U/L 
 AST……………………U/L 
 ALT……………………U/L 
Abdominal U/S: 
…………………………………………………………………………………
…………………………………………………………………………………. 
HEV   IgM ………………………… 
HCV   Ab…………………………… 
HBV   sAg………………………….. 
HAV   IgM………………………….. 
 
Diagnosis: 
 HEV                  Yes                     No 
      
 
